Experimental treatment shows improved protection against intestinal injury in mice, suggesting potential therapeutic applications.
Radiotherapy is constricted by collateral normal tissue injury during treatment, particularly the gastrointestinal tracts, which is usually referred as radiation-induced gastrointestinal syndrome (RIGS). Currently, there is no FDA-approved agent for the prevention or treatment of RIGS. By using a mice model of RIGS, we demonstrated that 1,2-propanediol (1,2-PD) prevents radiation-induced fatal intestinal injury and significantly increases mice survival following lethal doses of radiation. 1,2-PD pretreatment also enhanced the survival of Lgr5⁺ISCs and improved crypts regeneration after radiation. Moreover, we confirmed 1,2-PD induces dormant cell cycle arrest in enterocytes and ameliorates DNA damage both in vitro and in vivo. Although we did have observed 1,2-PD pretreatment inhibiting P53-PUMA signal pathway, but fail to prove its relation with radiation resistance. In RNA sequencing, we have observed 1,2-PD pretreatment significantly upregulates the Hif-2α, Hif-3α and PPARα target gene ACOX2, whilst downregulating the cell cycle drivers E2f3 and Cyclin D2. These results demonstrate that ISCs play a key role in radiation-induced intestinal regeneration and that 1,2-PD acts as a potent intestinal radioprotector.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: